| umls-concept:C1328025 | skos:definition | NCI: A monoclonal antibody that is being studied in the treatment of cancer. Monoclonal antibodies are produced in the laboratory and can locate and bind to cancer cells.,PDQ: A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322808&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=322808&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_The | lld:umls |
